CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer

[1]  Jung-Young Shin,et al.  Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[2]  S. Billan,et al.  Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer. , 2013, The Israel Medical Association journal : IMAJ.

[3]  F. Khuri,et al.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[4]  G. Calais,et al.  Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Guo,et al.  Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Kamatani,et al.  An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel , 2012, Cancer Chemotherapy and Pharmacology.

[7]  E. Genden,et al.  Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. , 2011, Oncology reports.

[8]  E. Tan,et al.  The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients , 2011, Cancer Chemotherapy and Pharmacology.

[9]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Yusuke Nakamura,et al.  Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia , 2008, Cancer science.

[11]  T. Gorlia,et al.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.

[12]  A. Markoe,et al.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.

[13]  R. Hitt,et al.  DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Taron,et al.  Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Jacobs,et al.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.

[16]  Jacques Bernier,et al.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. , 2004, The New England journal of medicine.

[17]  S. Lange,et al.  Adjusting for multiple testing--when and how? , 2001, Journal of clinical epidemiology.

[18]  D. Keppler,et al.  Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide* , 2000, The Journal of Biological Chemistry.

[19]  R. Corvò,et al.  Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer. , 2012, Anticancer research.

[20]  N. Barth,et al.  A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer. , 2012, American journal of otolaryngology.

[21]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.